T2 Biosystems, INC

T2 Biosystems reports a significant overhaul of its leadership team, including the resignation of multiple directors and officers, and the appointment of Craig R. Jalbert as the new CEO, President, Corporate Treasurer, and Corporate Secretary.

T2 Biosystems, following a significant workforce reduction, is actively seeking a sale of its assets, including patents and intellectual property, with the assistance of an advisory firm.

T2 Biosystems faces delisting from Nasdaq, implements a significant workforce reduction, and restructures executive roles through consulting agreements.

T2 Biosystems faces delisting from the Nasdaq Stock Market due to non-compliance with listing rules and will transition to the OTC Markets system.

T2 Biosystems has modified its term loan agreement, extending key payment deadlines and altering interest terms to improve its financial position.

T2 Biosystems announced record product revenues for both the fourth quarter and full year 2024, driven by strong sepsis test sales and strategic partnerships.

T2 Biosystems' Q3 2024 results show increased product revenue but ongoing losses and substantial doubt about the company's ability to continue as a going concern.

T2 Biosystems reported its Q2 2024 financial results, highlighting ongoing losses and concerns about its ability to continue as a going concern.

T2 Biosystems reported a net loss of $13.5 million for the first quarter of 2024, while also expressing substantial doubt about its ability to continue as a going concern.

T2 Biosystems' 10-K filing outlines its share structure, regulatory environment, and ongoing efforts to commercialize its diagnostic products.

Seymour Liebman, a director at T2 Biosystems, was granted 25,000 restricted stock units (RSUs) that vest in two equal annual installments.

T2 Biosystems' Chief Commercial Officer, Brett A. Giffin, was granted 360,000 restricted stock units (RSUs) on November 4, 2024, which vest over time.

Director Laura Lee Adams was granted 25,000 restricted stock units (RSUs) in T2 Biosystems, which will vest in two equal annual installments starting November 4, 2025.

Director John Cumming of T2 Biosystems was granted 35,000 restricted stock units that vest in two equal annual installments.

T2 Biosystems' General Counsel, Michael Terrence Gibbs, was granted 380,000 restricted stock units (RSUs) on November 4, 2024, which vest over different periods.

A T2 Biosystems director, Ninfa Saunders, was granted 25,000 restricted stock units (RSUs) that vest in two equal annual installments starting November 4, 2025.

T2 Biosystems is asking shareholders to approve a reverse stock split, with a ratio between 1-for-10 and 1-for-100, to regain compliance with Nasdaq's minimum bid price requirement.

T2 Biosystems will hold its 2024 Annual Meeting of Stockholders virtually on December 30, 2024, to vote on director elections, an incentive plan amendment, and the ratification of its independent auditor.

T2 Biosystems is asking stockholders to approve a debt-to-equity conversion with CRG that could result in CRG owning a significant portion of the company's common stock.

T2 Biosystems is offering up to 3,322,259 shares of common stock along with warrants in a public offering to raise capital for working capital and general corporate purposes.

T2 Biosystems is undertaking a public offering of common stock, pre-funded warrants, and common warrants to raise capital for working capital and general corporate purposes.

T2 Biosystems is offering shares of common stock, pre-funded warrants, and common warrants in a bid to secure additional working capital.

Jacob Safier and JSAF Holdings, LLC have disclosed a 5.3% beneficial ownership stake in T2 Biosystems, Inc., holding 1,500,000 shares of common stock.

Jacob Safier and JSAF Holdings, LLC have disclosed a 5.3% beneficial ownership stake in T2 Biosystems, Inc., holding 1,500,000 shares of common stock.